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ELSI  issues of Precision Medicine 
- Comparison of US, South Korea, China and Mongolia 





This study aims to review current precision medicine, analyze ELSI issues and  compare 
legal and regulatory framework of  informed consent and privacy issues in countries, 
namely US, South Korea, China and Mongolia. This has been conducted through analysis  
of current situation and challenges that four countries are facing in terms of informed 
consent and privacy issues in precision medicine.   The purpose of this study is to develop 
recommendation for Mongolia based on three countries experiences and pros during 
development of precision medicine regarding  informed consent and privacy.  
 
In order to carry out this study, mainly two study methods are applied. First, the literature 
review was performed with academic articles and reports on precision medicine and its 
ELSI research including informed consent and privacy issues, and officual documents from 
each government website.  Secondly, the comparative analysis of the legal and regulatory 
frameworks that relate to informed consent and privacy on prevision medicine was 
conducted in four countries.  
 
Through the analysis, it has clearly revealed that Mongolia need to improve regulation 
related to informed consent, including appropriate language and terms, evaluation 
questions and approval of electronic version. But in Mongolia, special contemplation 
 vi  
should be discussed in order to develop electronic informed consent due to nomadic life, 
lack of infrastructure, like internet, computer in remote areas, and low computer and health 
literacy, especially in non-capital areas. Since Mongolia is taking first step in privacy 
protection in context of personal information and sensitive information including genetic 
and biometric, several updates and recommendation could be proposed based on described 
approaches and solution ways from respective countries. This includes official 
implementation of PIPL, development of guideline for de-identification of personal 
information and building capacity for human resources and technology. Moreover, 
experience from developed countries can help improvement but approach need to be 
naturalized accordance with Mongolian background. 
 
Even though Mongolian government is started to focus on biomedical researches and 
related issues to enhance quality of research field and open more gates to researchers, 
infrastructure preparedness has developed very slowly. Recommendations arise from this 
study, may provide some opinions in building better frameworks targeting informed 
consent and privacy issues in Mongolian situation. Furthermore, detailed analysis from 
expert’s perspective will need to be conducted for achieving successful results with 




Keywords: Precision medicine, ELSI, informed consent, privacy, legal and regulatory 
frameworks
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Across the globe, new generation of research, especially genome related, has been 
promoted in recent years due to development of advanced technologies and large-scale 
databases, like biobank, with big data. Particularly in biomedical science, these 
developments play big role as future of diagnosis and treatment of diseases. The task is that 
how we can use them effectively in healthcare fields to tackle the diseases, like cancer, 
diabetes, cardiovascular and so on in era of increased life expectancy.  
 
Researchers have been going deeper into genome to discover mystery of diseases 
development with the rapid growth of scientific knowledge and analysis methods of data 
and genetics. This attempt has started with Human Genome Project (HGP) and now, it is 
“precision medicine to develop disease treatment and prevention that seeks to optimize 
effectiveness by considering individual characteristics in genes, lifestyle and environment”. 
1   In order to fulfill it, President Obama announced Precision Medicine Initiative (PMI) in 
United States (US) in 2015 2  and following it, other countries, such as South Korea, United 
Kingdom (UK), Japan 3, China and France 4 initiated precision medicine research as one of 
their national strategic plans.  
 
On the other hand, there are ethical and legal issues related to not only the precision 
medicine but also, human genome studies 3, 5. The research for these issues such as privacy, 
genetic discrimination, genetic testing and so on is called ELSI program which first 
implemented during the HGP in US. 6  Since implementation of precision medicine, several 
challenges and concerns, related to ELSI, have been identified and discussed. 3, 7 Especially 
 2 
concerns regarding genetic privacy, data protection, public awareness and informed 
consent are included. Based on the discussion and characteristics and limitation of the 
countries, it is required to improve current situation for national strategy because precision 
medicine requires more advanced approach comparing to traditional research. 8  
 
However, implementation of precision medicine has not initiated as national plan in 
Mongolia which requires experience-based learnings from countries, such as US, South 
Korea, China and many others. Also, there have been few studies that compares legal and 
regulatory frameworks in Asian countries and national strategy in developed countries. 3, 8, 
9 Yoshizawa et al. (2014) showed the differences regarding regulatory frameworks in East 
Asian countries, and significance of ethical review and informed consent based on 
country’s characteristics. 8 Minari et al. (2018) highlighted concern related to ethics and 
policy in implementing precision medicine, lessons from US, UK and Japan. 3 However, 
these studies showed limitations, i.e. concentrated on developing or developed countries 
that are not included Mongolia for comparison, and lack of detailed review of informed 










Based on the above background information, the aims of this study are determined as 
follows:  
 
1. To review the concept and characteristics of precision medicine in US, 
South Korea and China. 
2. To study ELSI challenges and practices and focusing on informed consent 
and privacy issues from ELSI research in precision medicine. 
3. To conduct a comparative analysis for regulation, guidance and 
improvisation experiences corresponding informed consent and privacy 
issues and  







This study is aimed to review current precision medicine and analyze ELSI issues and 
regulations relating to informed consent and privacy issues in countries, namely US, South 
Korea, China and Mongolia. Selection of these countries is due to influence of precision 
medicine to Mongolia, especially current initiation of collaboration between China and 
Mongolia in private sector. In addition, US is selected as original and well-achieved 
country for precision medicine initiative and South Korea as one of Asian country that 
implemented precision medicine and comparator to China. 
 
In order to carry out this study, mainly two study methods are applied. First, the literature 
review was performed with academic articles and reports on precision medicine and its 
ELSI research including informed consent and privacy issues, and official documents from 
each government. Second, the comparative analysis of the legal and regulatory frameworks 
that relate to informed consent and privacy on precision medicine was conducted in four 
countries. The academic articles which are published between 2015-2021 have been 
collected through PubMed, Google Scholar and Medline databases. Official documents, 
including legal and regulatory frameworks and guidelines, were collected through 
government and project official websites which provided the latest and original documents. 
(Figure1) Few of official documents were translated into English using Google translate 
due to lack of official translation.  
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Figure 1. Research Methodology  
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Chapter 2 Precision medicine 
 
 
2.1 Definition of precision medicine 
 
The term “precision medicine” has been introduced more widely over recent years as 
scientific perspectives in many countries. It has first defined in the report called “Toward 
Precision Medicine” by National Research Council (NRC) in 2011 which refers to “the 
tailoring of medical treatment to the individual characteristics, like life style, genetic and 
environment, of each patient”. 10 As mentioned in the report, it does not mean that new 
drug or treatment will be created for each patient but it will classify population into 
subgroups based on disease characteristics, prognosis or their response to specific treatment. 
There are many similarities between the terms “precision medicine” and “personalized 
medicine”. According to the NRC, “precision medicine” is a new term with meaning 
similar to “personalized medicine”. However, some experts still debate that the two terms 
are different from each other. 11, 12 The differences may reflect perceptions of how research 
participants acknowledge and react to the terms.  
 
As the Precision Medicine Initiative Cohort Program initiated in 2015, the PMI-Working 
Group had developed the report to the National Institutes of Health (NIH). According to 
the report, precision medicine is “an approach to disease treatment and prevention that 
seeks to maximize effectiveness by taking account individual variability in genes, 
environment and lifestyle”. And they believe that with help of more advanced technology 
and instruments, precision medicine tries to specify and understand about onset and 
development of disorders, treatment response and health outcomes. 13 
 
The National Health Service (NHS) defines precision medicine as a tailored approach that 
could better manages patients’ health and outcomes through the use of targeted therapies 
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with genome sequencing, personalized data and other technologies. 14 In South Korea, the 
Ministry of Health and Welfare formed the Precision Medical Research and Development 
Promotion Committee in 2016 to promote the industrialization of precision medicine. In 
this meeting, precision medicine is stated as a customized predictive medicine that 
integrates personalized medicine (genome medicine) that considers the genome and clinical 
information, and mobile healthcare based on health, life environment and habits 
information. 15 
 
However, there is no official definition that is determined by China yet, Chinese experts 
who are participated in Precision Medicine and Policy Summit in 2018 are defined 
precision medicine as “a new medical model that combines modern technologies and 
traditional medical techniques to improve the understanding of human mechanisms and 
diseases to achieve optimal outcomes for the health of individuals and the general public 
through care provided in a more efficient, safe and affordable manner”. 16 Although there 
is a little difference in definition of precision medicine in countries due to customization 
of local context, overall components that are applied in precision medicine research, such 
as cohort study, are same with each other. Along with definition, its translation and 
explanation need careful consideration to make it comprehensive not only for public, but 
also for professionals.  
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2.2 Components of precision medicine 
 
There are several key components for implementation of precision medicine. One of those 
components is big data derived from participants and community to understand disease 
biology and pathogenesis, and providing better health both in individual and population. 
Over decade, reduction in the cost of data storage have enabled large scale data collection 
with advanced information technology (IT), digital health information systems, such as 
electronic health records (EHR), and mobile technologies. 13 Data derived from these 
sources are analyzed using advanced methods to discover new connection of disease factors. 
As much as data, data collection and its management are essential in successful precision 
medicine.  
 
As IT is advancing rapidly these years, many countries have developed and now, are using 
national integrated health information system, electronic medical records (EMR) or EHR 
in the hospitals to collect patients’ health data, such as medical history, laboratory or 
radiology results, and treatment, timely and safely as a source of big data. 1, 17 When 
conducting study to build data platform in precision medicine, survey and interview from 
participants and wide spread use of wearables are another source of data collection, with 
EHR/EMR. Since these collected data includes sensitive and personal information, data 
access control and maintenance of privacy should be managed accordance with study 
protocol and regulatory frameworks. 18  
 
The second component is genetic profiling of the individual with rapid DNA sequencing 
methods. 19 Due to limitation of characterized genes which are clinically applicable, there 
were many problems, such as cost and lack of advanced technology in gene sequence 
analysis of individuals. However, with advanced sequencing tools, current next sequencing 
technologies allows to include more comprehensive genetic analysis. 20, 21 Comparing to 
thirty years ago, genome sequencing time and cost of genetic information extraction have 
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been decreased dramatically which have led to expansion of genetic research and genetic 
testing. 22 But, developing countries, which are new to genome sequencing or lack of 
experts and infrastructure, need international collaboration to adapt tools with sufficient 
education as well as government support, especially in regulation and funding. 23  
 
The precision medicine connects patients, providers, clinical laboratories, researchers and 
policymakers which is the third component, to provide infrastructure for further co-
operation and aim to set framework for health and disease management for everyone. For 
data collection, patients or participants provide health-related data with biospecimen which 
are the main source of data. Also, in recruitment of the participants, many studies are 
including rare disease or specific-diseases patients but there are several favors over healthy 
individual, such as early detection of disease risk and preventive health strategies. 3 
Researchers and clinicians analyze these data using advanced technologies to understand 
mystery of diseases and develop new treatment.  Since precision medicine is a new 
scientific approach to promote integration of research findings and evidence-based 
interventions into clinical practice, government support and decision-making from 
policymaker are very influential for building infrastructure and further regulation at 
national level. 24 Without relevant legal regulation, guidelines or strategy in precision 
medicine development, protection of data privacy, accessibility of valid genetic 
information and quality of tests and services cannot give assurance to patients and public 
in clinical practice to improve health outcomes. 25 
 
To create a research repository that is consisting of medical records, physical measurements 
and biospecimens with follow-ups over a period of time for precision medicine, national 
cohort study have been conducting as base of precision medicine in US, South Korea and 
China. 18 For instance, a cohort study of more than 1 million people was established in US, 
and general and specific-disease population cohort studies are ongoing in South Korea and 
China. All of these cohort studies are collecting participants’ health data, such as medical 
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history, lifestyle, family history and so on, physical measurements and biospecimen 
samples for further DNA analysis. 
 




The precision medicine is a long-term research to understand how individual’s genetics, 
environment and lifestyle can help determine the best approach to prevent or treat diseases 
by integrating with advanced technologies like biomedical big data and artificial 
intelligence. In 2015, the Precision Medicine Initiative was first made public by President 
Barack Obama. The President announced that $215 million investment in total will be 
provided to the NIH, the National Cancer Institute (NCI), the Food and Drug 
Administration (FDA) and the Office of the National Coordinator for Health Information 
Technology (ONC) for development of national research and database with privacy and 
security of personal information. 13 
 
Current medical treatments have been outlined for the “average patient” so that every 
patient have not shown same effectiveness from the treatment which is called “one-size-
fits-all approach”. 26 But with help of novel approach, precision medicine, each individual’s 
variability in gene, environment and lifestyle will be considered for disease prevention, 
diagnosis and treatment. 2 According to objectives of the PMI, NIH has launched national 
cohort program called the All of Us Research Program (AURP) to enroll at least 1 million 
individuals. Participants will share their EHR data by giving a consent and answer prepared 
survey, provide biospecimens, such as blood and urine, for genomic and other laboratory 
assessments, and give physical measurements. The AURP initiated the enrollment in May 
2018 and enlist participants who are 18 years of age or older from a network of more than 
340 sites. 27 
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The AURP has developed two methods for participant recruitment and enrollment. The 
first method is that healthcare provider organizations (HPO) enlist participants from their 
patients. The second one is volunteers who want to enroll the program apply by using 
website or smartphone.  Those participants should firstly complete the electronic consent 
modules which include videos with explanation, health surveys and questions, and provide 
permission for access to their EHR. All question and surveys (Table 1) are prepared in 
English and Spanish with sample terminology so that, every participant can understand 
easily. 28 
 
Table 1. Types of data collection and it details in the All of Us Research Program 
Type Name Details 
Core* 




- Marital status 
- Health insurance and disability 
- Income and address 
- Contact number, address and person 
Lifestyle - Smoking 
- Alcohol usage 
- Drug substances, including cocaine, gas 
and etc.  
Overall Health - Health status including physical and 
mental 
- Quality of life 
- Questions for women 




- Heart and blood conditions 
- Lung conditions 
- Cancer conditions 
- Digestive conditions 
- Hormone/endocrine conditions 
- Kidney conditions 
- Bone, joint and muscle conditions 
- Hearing and eye conditions 
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Type Name Details 
- Infectious diseases 
- Brain and nervous system conditions 
- Mental health and substance use 
conditions 
- Others (obesity, vitamin deficiency, so on) 
Health care access 
and utilization 
- Health insurance or coverage 
- Health care services from doctor, nurse, 
midwives or specialists 




- Health problems in relatives 
- Mother’s condition 
- Father’s condition 
- Brothers and sisters’ condition 
- Daughter’s condition 
- Son’s condition 
- Grandparents’ condition 
* National Institutes of Health - All of Us Research Program. https://allofus.nih.gov/ 
 
The program also collects health data from EHR which is a digital version of medical chart, 
under participants’ permission. This record includes participants’ health problems, 
received health care services such as medication, laboratory and radiology tests, and 
medical and surgical procedures. Since it includes sensitive and private data, the program 
provides explanation of what EHR is and how they are going to use with security and 
confidentiality to the all participants. The program will access to EHR data of participants, 
who are enrolled by HPO, though HPO whereas volunteers will share their EHR through 
health information exchange.  
After completion of survey and sharing EHR data, all participants provide their physical 
measurements and biologic samples at HPO or contracted clinic. Physical measurements 
include blood pressure, height, weight, waist and hip circumference, and heart rate. Adult 
participants provide up to 50 ml of blood and 50 ml of urine, in case where it is not possible 
to obtain blood sample, a saliva sample can be collected instead for purposes of isolating 
DNA. Collected biospecimen will be shipped and stored in the Biobank at Mayo Clinic. 18 
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All participants’ EHR, health survey, physical measurements and sample data from 
biobank are added into the All of Us scientific database, a common cloud environment. In 
order to use the database, researchers have to be approved by the All of Us Resource Access 
Committee as passport-model and then, permission will be provided to the researchers to 
use web-based tools and cloud-based computing for inspect the collected data. Personal 
information, like name, social security number etc. is removed (de-identification) from the 
data which is available for the researchers. In addition, participants or public also can 
access to dataset using data browser tool (https://databrowser.researchallofus.org/) while 
approved researchers are available to data using Researchers Workbench, as private.  The 
security of software platform (web-based) has been assessed in accordance with the Federal 
Information Security Management Act. Most result of research testing and participants’ 
own physical measurements are open to participants in AURP. 27 Moreover, when there is 
a risky genetic variant which can cause serious diseases, participants will be informed about 
it. As the program continues and number of participants increases, they keep improving 
and developing advanced and secure technologies for the data privacy and others. 18 
 
2.3.2 South Korea 
 
Following PMI in US, Korean National Institute of Health and U.S. counterpart signed a 
Letter of Intent (LOI) for collaboration on precision medicine research on October, 2015. 
29 Through this, efforts for international cooperation in the field of precision medicine were 
started, such as initiating joint research program, solving funding issues and strengthening 
human resources and training. In 2016, precision medicine was selected as one of the nine 
field of national science and technology strategy project. In this meeting, it is planned to 
establish precision medicine cohort that collects genetic, medical, lifestyle and 
environment information of at least 10,000 individual, and develop data integrated-system 
of genomes, medical and health status for easy accessing from hospitals and related 
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healthcare or pharmaceutical companies. 30 In addition, genomic information of 100,000 
Koreans’ three major cancers, including lung cancer, stomach cancer and colon cancer, is 
planned to secure for personalized anti-cancer diagnosis and treatment  development and 
further to initiate chronic disease management programs with advanced mobile 
technologies. 30 
 
At the same time, Korean government announced new 2 national strategic projects to 
integrate precision medicine with healthcare more accurately in 2017. The first one is the 
Precision Medicine Hospital Information System (P-HIS) and other one is The Precision 
Medicine-Based Cancer Diagnosis and Treatment development (K-Master). The both 
projects are led by Korea University Medical Center (KUMC) under supervision of the 
Ministry of Science and ICT and MOHW. The project is anticipated to highlight new 
paradigm in the national medical system by developing new cancer treatments based on 
precision medicine and establishing cloud-based hospital information system with support 
of fund from the government. 31 
 
The K-Master project team was launched in June 2017 with the goal of expanding 
customized medical care through establishment and activation of a cancer diagnosis and 
treatment platform based on precision medicine in order to improve the national health and 
quality of life along precision medicine. With the project, genome analysis of 10,000 
Korean who are recurrent and metastatic cancer patients, is planned to be conducted for 5 
years to develop nationwide genome screening protocol. The cancer genome analysis 
program started with Korea University Anam Hospital in October 2017 and as of April 
2019, a total of 52 institutions nationwide are participating. 32 By January, 2021, The K-
Master project group had registered a total of 8,695 cancer patients, of whom 8,271 had 
undergone genome profiling and 7,902 had obtained reports of genome analysis findings. 
It is anticipated that the genome analysis of 10,000 cancer patients will be completed. 33 
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Moreover, in 2019, the Ministry of Health and Welfare announced the 2020 R&D Project 
Integrated Implementation Plan that contains the National Project of Bio Big Data 
Construction as one of the seven key directions. This is a research program that collects 
and analyzes genetic information data of one million people. 34 Through the study of the 
genetic characteristics of Koreans, diseases that are vulnerable to Koreans can be predicted 
in advance and used in medical treatment and treatment development research. 35 This 
project aims to build a system in which Koreans’ health information and genetic 
information are collected through voluntary participation of the people, managed in safe 
platform and analyzed by qualified researchers. Because personal genetic information is 
very sensitive, the data must be managed and protected at the public and governmental 
levels. The project is in cooperation with four governmental departments, four government-
funded research institutes and sixteen national hospitals. As the first step in the national bio 
big data construction project, Korean government plan to build clinical information and 
genomic data through recruitment of rare disease patients first. 36  
 
During the project, clinical information, including basic information, disease information, 
health status information, and disease-related information are collected through interview 
and medical records at other institutions’ data (EMR). In addition, for genomic data, blood 
and urine, (alternatively saliva) are collected less than 40 ml and 25 ml (2ml), respectively 
from the adult participants. All this information will be stored in the National Integrated 
Bio Big Data Platform. The resident registration number is only used for the purpose of 
linking with the health-related information of the participant stored in public data sources 
and medical institutions holding medical records. Those are “Death data from Statistics 
Korea”, “National Health Insurance Service’s medical and examination data”, “Health 
Insurance Review and Assessment Service’s data” and “Cancer registration data from 
National Cancer Center”. 36 From the National Integrated Bio Big data Platform, general 





Precision Medicine Initiative was introduced into China’s 13th five-year plan in 2016 by 
the government, with an estimated $9 billion which is the largest comparing to other 
countries spent on research and development. 37 As the development of precision medicine 
in China entered a period of acceleration, the Ministry of Science and Technology released 
a national key development plan, and “Precision Medicine Research” was announced as 
one of the priority project to be launched in 2016. In this plan, four-research directions of 
precision medicine were included. The first direction is research and development of new 
generation of clinical technology for future precision medicine. The second one is large-
scale population cohort study which divides into two subgroups, general population and 
disease-specific population. In general population cohort study, especially two main 
regions are selected, conducing 100,000 population each. 50,000 participants each for rare, 
cardiovascular and metabolic diseases, and esophageal and breast cancers are planned to 
be recruited for disease-specific cohort study. The third is construction of platform for 
resource integration, storage, utilization and sharing of precision medicine big data. And 
the last one is precision research on disease prevention, diagnosis and treatment plan which 
will be the key result and integration of all study. 38 
 
Moreover, accordance with the plan, the Ministry of Science and Technology’s “Precision 
Medicine Research” invested in 61 cohort studies for period of five-year with various types 
of disease-specific, especially rare disease, and general population from the most part of 
the country. During these cohort studies, 30-79 years of participation enrolled voluntarily 
by providing questionnaire surveys, medical examination, and bio samples for laboratory 
test and biobank (genetic variants). As strongly supported by every level of government, 
and CDCs, cohort database is linked with National Death Surveillance System (NDSS), 
Chronic Disease Registries (CDR) and National Central Canter Registry (NCCR) to allow 
credible and timely check of the participants’ health condition as well as five-year follow-
up. 39, 40  
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On the other hand, china is at the forefront of data collection and analysis methods for 
studying human genetics and biology. The Beijing Genome Institute is the world’s largest 
sequencer and archive of genetic material – the DNA code that distinguishes everyone. 
Besides, as early of 2017, the Beijing Genome Institute’s China National GeneBank in 
Shenzhen had over 500 million genetic sequences from over 8,000 species deposited in 
more than 40 databases. 37 It is believed that the advancement of computational power and 
artificial intelligence systems to discover new medicines and therapies, and bring them to 
the right patients is another power of China in precision medicine.  
 
In company with the government, there are private big organizations, such as iCarbonX, 
WuXi NextCODE, CloudHealth Genomics and so on, which are taking a big part in data 
collection and AI data mining, cloud-based platform of massive amount of data, database, 
and precision medicine solutions. In particular, with over 20,000 Chinese individuals, 
CloudHealth Genomics has one of the biggest Chinese population whole genome 




In Mongolia, precision medicine related cohort study like in US, South Korea or China has 
not initiated officially yet at national level. However, Shanghai-based CloudHealth 
Genomics and the Mongolian Health Initiative (MHI) signed collaboration in advance 
precision medicine research for nutrition deficiencies and nutrition-related diseases during 
the Central Eurasian Nutrition Forum which was held in Ulaanbaatar, Mongolia. (The 
launch of CloudHealth Genomics-8) The MHI is a non-governmental research organization 
focusing on health issues such as tuberculosis and vitamin D deficiency. 42 The 
CloudHealth Genomics, Ltd., is the one of leading company in China focused on whole 
genome tests and providing genomics-based precision medicine and scientific well 
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solutions. This collaboration is aimed to create new diagnostics and therapeutics by 
identifying biomarkers for nutrition-related diseases with innovation of biomedical 
research. 43 It was confirmed that data and results would be made public in the future. 
Additional information accordance with research were not disclosed. This initiative is only 





Table 2. Comparison of precision medicine programs in US, South Korea, China and 
Mongolia.  




2015 PMI – 
All of Us 
Program  
2017 – 2021  
The K-master 
project 








1,000,000 10,000 1,000,000 - 
Focus Cancer Cancer (stomach, 






Budget  $215 million $55.7 million $9 billion - 




EMR -  




Blood and urine Blood, urine and 
saliva 
- 
*National Institutes of Health – All of Us Research Program. https://allofus.nih.gov/ 
**K-MASTER Cancer Precision Medicine Diagnosis and Treatment Enterprise. 
http://k-master.org  
***Ministry of Science and Technology. The People’s Republic of China – Precision 
Medicine Initiatives in China. http://most.gov.cn  
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Chapter 3. Informed consent and privacy as issues of 
genomic study  
 
3.1 Ethical, legal and social implications (ELSI) 
 
3.1.1 Initiation of ELSI research  
 
In the mid-1980s, the Human Genome Initiative started to highlight the development of 
resources and technologies for genome mapping and sequencing that would lead to the 
entire human genome map in the worldwide. During planning stages of the HGP in 1990s, 
it was accepted that the ethical, legal and social aspects of genomics research are influential 
to successful development and progress of the project. This acknowledgement led to 
formation of ELSI Program which has supported and funded many projects related to ELSI 
research at NIH. 44 It was believed that ELSI will give support on solutions to the potential 
problems raised from HGP prior to integration of genetic information and modern health 
practices. 45 
 
Francis Collins et al. (1998) outlined focus points for the ELSI research Program in the 
HGP strategic plan for 1998-2003. These goals are (1) to look at the issues surrounding the 
human genome’s completion and the analysist of genetic variation; (2) to examine the 
challenges posed by the integration of genetic technologies and knowledge into healthcare 
and public health activities; (3) to examine the problems posed in non-clinical settings by 
the integration of genomics and gene-environment interactions expertise; (4) to investigate 
how modern genetic understanding interacts with various philosophical, religious and 
ethical viewpoints; and (5) to study how racial, cultural and socioeconomic factors 
influence the usage perception, and understanding of genetic knowledge, as well as the use 
of genetic services and policy creation. 46 
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As it was mentioned before, ELSI provides a new approach to scientific study by 
discovering, assessing and discussing the ethical, legal and social implications of human 
genetics research while the fundamental science is being studied according to the HGP 
until 2003. 6 Even though HGP completed in 2003, it did not conclude the ELSI Research 
Program.  On the contrary, as the ELSI Program showed good influences and results in 
HGP, many other areas of research, such as biology, neuroscience, nanotechnology, big 
data and precision medicine are applying into ELSI research, not only in human genomics 
and genetics. 47 The countries which launched Precision Medicine, has anticipated some 
potential ELSI, as demonstrated by its attention to cohort diversity, privacy and security, 48 
genetic discrimination 49, participant engagement and data sharing and accessibility. Along 
with ELSI program in U.S., European countries, Canada and South Korea have also 
initiated ELSI program in not only genomics although their acronyms are varying from 
each other. 50 
 
In European Countries, ELSI program was called as ELSA which is an acronym for ethical, 
legal and social aspects of emerging sciences and technologies and it was implemented two 
decades ago, in the form of the 4th EU Framework Program (launched in 1994), to frame 
problems and to fund research, stakeholder dialogue, education, and other activities to 
resolve them. Since then, other initiatives, especially in European partner countries, have 
adopted the ELSA research, such as the ELSA program for the Research Council of 
Norway and ELSAGEN to fund research on ELSA issues of genomics and other associated 
sciences (a partnership of research funding agencies in Germany, Austria and Finland). 50 
Throughout Europe, ELSA programs were not only gaining interest and integration with 
other fields, but also, faced challenges and arguments from researchers. Recently, the 
concept of ELSA started to change into Responsible Research and Innovation (RRI), 
especially in the light of recent EU funding initiatives (notably Horizon 2020). RRI is a 
science policy paradigm that aims to expand innovation process and support collaboration 
for innovation with other fields. 51 There are five European Commission RRI keys, 
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including ethics, societal engagement, gender equality, open access/science and science 
education. 52 
 
The Ministry of Science and Technology of South Korea initiated ELSI Program in 2001 
as the Frontier Project, including studies in the humanities and social sciences, following 
the ELSI Research Program of United States. ELSI Program of human genome project in 
Korea focused on development of ethical guidelines in human genome research, suitable 
informed consent form 53, ELSIKOREA database and research infrastructure. 54 During this 
time, the ELSI concept was expanded to include ELSI of Nano 55  and neurotechnology, in 
addition to ethical, legal and social implications of biotechnology, especially in genomic 
and precision medicine. This expansion represented an expansion of the broader collection 
of research areas that were now given priority, which are sometimes referred to as 
“emerging technologies”. It shows the importance of ELSI in scientific researches in 
various types of fields.  
 
3.1.2 ELSI challenges in Precision Medicine  
 
Since inception of ELSI Program in HGP, the program set goals to address major issues of 
the HGP and develop initial policy options. These issues are fairness, privacy and 
confidentiality of genetic information, genetic counselling, genetic information on medical 
practice, and uses and misuses of genetics. 6 As a result, ELSI research has showed many 
impacts, produced policy outcomes, and accomplished improvements in genomic research 
and genetics. 44 One of the accomplishments of ELSI research can be shown in upgraded 
informed consent form for genomic research. With understanding of harms and benefits 
related to genetic research during ELSI Program, ethical review, the drafting and trends in 
consent forms has changed to protect participants and research subjects as well as gain 
public trust. Even issues that are addressed in the research shows importance, it is difficult 
that all of the research results can arise impact on policy outcomes.  
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Due to novel technology approaches and increased use of personal health related 
information, such as medical history and genetic information from various sources in new 
era of precision medicine, ELSI associated issues have becoming more challenging for 
researchers and policymakers, and it requires new approach and analysis of situation and 
in context of these issues. Many researchers from various countries that has implemented 
precision medicine have been conducting ELSI research and addressing ELSI issues based 
on experiences and outcomes from the HGP-ELSI Program. Brothers et al. (2015) 
addressed issues related ELSI in personalized medicine, similar to precision medicine 
approach. According to their analysis, two broad issues are reviewed as significant, these 
are health information related concerns - privacy, discrimination, and healthcare disparities 
related concerns. 49  
 
Moreover, Adams et al. (2016) highlighted a number of ethical, legal, and social issues 
related to precision medicine in order to improve and upgrade existing principles and 
regulations that can be helpful to promote trust between patients and researchers/health 
professionals and achieve goal of precision medicine in healthcare. As stated by them, 
patient privacy and informed consent have been chosen and known as common issues in 
many researches which collect a large amount of medical and health related information 
from participants or patients, so those cannot be excluded from ELSI issues in precision 
medicine. 56 
 
In addition, advancements in next-generation sequencing technology have made it possible 
to large-scale sequencing with many opportunities in analysis of human genomes from 
biospecimens. Although it has helped the diagnosis and treatments in many undiagnosed 
rare disorders, and the identification of disease risks and cancer treatments, some 
consideration of practical and ethical implications are continuously drawing attention from 
researchers and clinicians. 57  To manage them, informed consent process need to be revised 
for well understanding of risks and benefits associated with research, as well as privacy 
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issues of their health information. Several studies in population survey regarding precision 
medicine cohort study found that participants’ the most concern is privacy about their 
health information and genetic information. 58, 59 Thus, consideration of ethical, legal and 
social issues in precision medicine will great help on conducting national cohort study for 
data collection and analysis, and achieving precision medicine goals in healthcare by 
understanding developments of diseases and discovering new diagnostic and treatments. 
 
3.1.3 Focused issues of ELSI  
 
Most countries started considering and analyzing ethical, legal and social issues along with 
the development plan of Precision Medicine. As Precision Medicine Initiative started in 
US, ELSI issues associated with PMI-AURP were addressed by organizer although PMI-
AURP have not initiated ELSI research independently. But funding announcement of the 
program showed main issues that are arising in context of ELSI. 48 In 2015, international 
conference titled “the Translation in Healthcare” held at the University of Oxford to discuss 
the ethical, legal and social challenges raised by novel healthcare technologies, and 
informed consent and privacy are themed as some of fundamental issues of ELSI according 
to studies 60, 61  focused on translation research of genomics, not only in US but also in UK. 
62 There are many debates about suitable paradigm to the traditional informed consent in 
terms of precision medicine. 5, 63 Moreover, in large and international networks, informed 
consent should be either universal or easily adaptable while still accommodating ethical, 
legal, social and cultural differences. 64  
 
At the same time, Finland have been conducting precision (personalized) medicine 
researches regarding concerns in traditional ethical issues and regulation due to new 
technology, Big data activities. This led to attention of developing innovation-friendly 
regulatory approaches and practices, which including revision of informed consent, and 
privacy and autonomy rights in Finland. 65 In China, Pang et al. (2020) pointed out key 
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ethical issues in field of precision medicine research as informed consent, returning of 
results and data use and sharing due to complex technology, large-scale sequencing, 
accidental or unexpected findings and uniqueness of genetic information. 66 Even though, 
update and adjustment to relevant law, policies and regulations need to be carried out in 
response to these challenges, there are some obstacles from the cultural side of China to 
proceed solution based on other countries experiences and principles, and it requires 
different solution way, i.e. genetic counselling.  
 
 
By analyzing articles and researches in many countries, informed consent and privacy are 
the most commonly addressed issues from ELSI and a lot of deliberation and debates have 
been labelled in order to cover scope of emerging technologies with upgradation of policy 
and regulation frameworks, even from lower level. Moreover, Based on ELSI discussion 
regarding precision medicine, revision of the act is proposed in some countries for solution 
of ethical challenges and achieve goals of precision medicine without risks and harms to 
the participations or public. With demand from ELSI research, policymaker and 
government officer are getting to understand importance of precision medicine and its 
effectiveness in legal and regulatory frameworks.  
 
3.2 Informed consent 
 
3.2.1 Background and key pillars 
 
Informed consent is a key component of conducting human research ethically. The biggest 
turning point in history with regard to human subject research is the Nuremberg Code (1947) 
that articulates the requirements of fully informed voluntary consent of the human subject 
or study participants. 67 The aim of informed consent, which is based on the ethical concept 
of respect for individuals, is to ensure that participants are aware of the risks and possible 
benefits of engaging in research as well as rights and make a voluntary decision. Even 
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Nuremberg Code was integrated into numerous human rights legislations, it had an indirect 
impact on the research community and there were still problematic or unethical studies, 
which contributed to be the creation of its own guidelines for human-subject research was 
approved by the World Medical Association in 1964 with title of Ethical Principles for 
Medical Research Involving Human Subjects and since then, there were several times of 
revision. 68 Following these regulations, every country has enacted their legal acts and 
guidelines related to ethical points of human-subject research, such as the Belmont Report, 
the Common Rule, and Bioethics and Safety Act. 69  
 
Most of official documents about informed consent define three main pillars or elements 
of informed consent as disclosure information, subject’s comprehension and understanding, 
and voluntary participation. 70 Disclosing all information about the study to the participants 
such as research procedures, the purpose of the research, risks and benefits, and any other 
information for subject need to know is crucial regardless the effect of the study. 71 In 
addition, comprehension of informed consent allows subjects or participants to understand 
all disclosed information before giving consent on participation. However, there are several 
factors that limits comprehension including illness, poverty, illiteracy or low level of 
education, especially health education, and unfamiliarity with conduct of medical research. 
72 To enhancing comprehension of informed consent, provision of information at the 
education level of the individual participant, comprehensibility of language and design 
regarding consent forms, and use of aids to easier understanding, such as pictures, 
animations, audiovisuals etc. are commonly used in biomedical research. 73  Another key 
pillar of informed consent is voluntariness which requires free of constraint and improper 
influence in participation as well as withdrawal. The voluntary withdrawal from research 
is rather recent in many countries with inclusion in the regulation, such as the Common 





3.2.2 Types of informed consent and challenges  
 
As innovations in technology advance at such a rapid speed, it is difficult to predict future 
risks related to research using biospecimens and data. Therefore, ethical standards of 
informed consent need to be reconsidered and finding a solution associated with these 
future problems in precision medicine is required. 74 For instance, various types of consent 
is being used in biomedical research field to overcome the limitations. One of the 
commonly used consents is broad consent that approves researchers to use data and 
biospecimens for future studies without additional consent but when it is within the scope 
of the consent. Recently, the use of broad consent is included in the Common Rule 
officially as alternative. 75  
 
While dynamic consent, new approach to consent, has been started to be implemented in 
several projects due to its integration with modern IT, others are blanket, tiered, and open 
consent that each has own advantages and limitations. 74 Such dynamic consent model 
enables alerting individuals of new research opportunities and processing consent 
documents in real-time by communication between researchers and participants. Blanket 
consent refers to a process by which subject donate their samples without any restriction in 
future studies but it may conflict with individual’s fundamental values and requires donors 
to be contacted constantly over time. However, it opens door for researchers to study 
biological materials in future studies without restriction, research participants’ protection 
is valued more precisely for ethical research. Tiered consent allows participants to choose 
general research areas they wish to participant in and exclude others. Moreover, 
participants can ask for re-consent when there is a use of their data.  
 
However, traditional conceptions of informed consent have been challenged by innovative 
developments in biomedical research, especially the increasing advent of large-scale 
 28 
population studies and DNA databases in era of precision medicine, there are a number of 
summons related to informed consent. Firstly, research participants often do not 
comprehend the contents of the study’s information sheet or the consent form for the study, 
particularly if the consent form is containing advanced terminology. 76 Also, many of 
consent forms are 15 to 20 pages in average which requires some time to read and 
understand. Due to its length and time, it is possible that participants are not reading the 
whole form, or not paying attention to researcher’s explanation and miss out critical 
information needed to make an informed decision. 77 Secondly, determining consent 
approach arises because traditional informed consent is designed one specific study during 
pre-arranged timespan but in the era of precision medicine research, collected data and 
biospecimens can be used for future studies and it is difficult to foresee all future uses and 
application of the data in the beginning of data collection. For instance, re-contacting 
participants to obtain additional consent for new usage can be one of solution, however this 
method may show impact on research participants as discouragement to participation and 
misunderstanding. 74 Depending on requirement of country and types of research, the 







Privacy defined as a condition restricting access to an individual or information about an 
individual. However, due to its complexity, there is no globally agreed definition of the 
term, and there is still debate about meaning, value and scope of the concept of privacy. 78 
In reaction to a wide range of privacy-invading technologies underlying applications in 
everyday use by government agencies and businesses alike, people’s expectation and 
understanding of privacy are rapidly changing, especially in recent years. To reduce 
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possibility of information privacy risks, a variety of technical protections have been 
implemented but still it does not prevent fully in various types of information. Furthermore, 
the notion of privacy mirrored in these technologies is changing over time, partially as a 
result of new vulnerabilities being discovered, a process that has increased dramatically in 
the last two decades. 79  
 
Recent advances in medicine, particularly the tendency toward precision medicine and 
learning health systems have resulted in substantial privacy protection. Especially in 
genetic and personal health-related data, the sensitivity, nature and future advantages, 
threats and uses of the data should all be considered every time by policymakers, 
researchers and legal scholars. 80 This is difficult task in an era where sensitive personal 
data is collected and processed on a large scale for determining and innovating precise 
diagnosis and treatment. In addition, reasons to importance of privacy protection are to 
prevent from stigma and discrimination in case of revealing of sensitive information, to 
improve quality of health care and to protect public from any health risks. As arise in 
collection, usage and analysis of health data from various sources for precision medicine 
research, public selects privacy as a top concern in everywhere, including US, South Korea 
and Australia. 58, 59, 81 Moreover, governments are also paying attention about privacy of 
health data, including personal and genetic information by developing policies and 
legislation as well as technical approaches to privacy protection.  
 
3.3.2 Data protection and challenges 
 
When it comes to health (health data) privacy policy and legislation, the principal is 
whether the information is personally identifiable. Such data flow freely if it is not 
personally identifiable, and it is not subject to the obligations imposed by the applicable 
privacy legislation. To protect privacy of data, privacy preserving methods have been used 
in stages of data collection, storage and processing. 82 In particular, there are some 
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techniques such as de-identification or anonymization for privacy protection in data 
processing and it is stated in the legislation of the countries. De-identification could be 
defined as the process to remove both direct and indirect identifiers of the data while 
pseudonymization is to replace identifiers in a set of data with artificial identifiers or 
pseudonyms. Pseudonymized data can be re-identified with integration of additional data. 
Anonymization refers to apply technical safeguards to de-identified data which has zero 
re-identification risk. 81 However, procedures and use of these techniques are varying in 
countries, especially in legal and regulatory frameworks. Therefore, the difficulties of 
generalizing and scaling de-identification and anonymization techniques, as well as the 
lack of widely accepted metrics to measure effectiveness of results, are frequently 
highlighted problems in several studies. 83, 84  
 
However, concerns about re-identification risks are rising due to the emergence of personal 
health data as well as genetic data which it cannot be confidently guaranteed that the data 
cannot be traced back to a person, and advanced technologies. 85 Due to the inability of 
totally de-identifying genetic information, genetic data and biological samples containing 
genetic material are often regarded to differ from other types of health data. The basic 
notion is that even though the individual’s name and other identifying details are removed, 
genetic data, itself, may still be connected back to the relevant individual and families. 86 
For instance, matching and connecting genetic data to non-genetic database, and profiling 
from genetic data to determine age, gender and even face figure are available due to 
advanced development of technologies, and have being used in some fields, like criminals 
to identify and determine the person from the genetic data. In order that, researchers should 
inform potential research participants about the risk of re-identification of genetic 
information that their identity could be discovered by anyone who obtains access to the 




Chapter 4. Comparison of legal and regulatory framework 
focusing on informed consent and privacy 
 
4.1 Informed consent 
 
4.1.1 United states 
 
4.1.1.1 Regulatory framework 
 
In 1979, the National Commission for the Protection of Human Subjects Biomedical and 
Behavioral Research issued the Belmont Report, entitled Ethical Principles and Guidelines 
for the Protection of Human Subjects of Research that provides three principles, including 
respect for persons, beneficence and justice for ethical research with human beings. 
Following this report, the Department of Health and Human Services (HHS) Common Rule 
(45 CFR Part 46) and the US FDA regulation (21 CFR part 50) were established as human 
subject protection regulation of all research involving human subjects by any federal 
department or agency, and of all clinical investigations regulated by the FDA, respectively. 
Both regulations define the requirement that are for legally valid informed consent, 
including electronic version with activities related to research policy in protection of human 
subjects. Recently in 2017, HHS revised the Common Rule which is officially effective 
from 2019 January. Accordance with the revised Common Rule, FDA updated 
requirements of informed consent to avoid the need for two separate information consent 
forms, 88 even though regulation related to clinical trials, as FDA regulation is independent 
from all research involving human subjects. Moreover, the informed consent form to 
represent the expansion of precision medicine and genomic analysis has started updating 




4.1.1.2 Requirements of informed consent 
 
Both HHS and FDA regulations require that certain basic and additional 
elements/information be given to each subject when obtaining informed consent. 89 
According to the regulations, there are 8 basic elements, including description of clinical 
investigation, risks and discomforts, benefits, alternative procedures or treatments, 
confidentiality, compensation and medical treatment in event of injury, contacts and 
voluntary participations.  Additional elements of informed consent are unforeseeable risks, 
involuntary termination of subject’s participation, additional costs to subject, consequences 
of subject’s decision to withdraw, providing significant new findings to subjects and 
number of subjects. 90 
 
In the revised Common Rule, general requirement for informed consent are changed into 
new standards and requirements regarding comprehension and length of the form. 
According to the revision, key information about the study must be provided at the 
beginning of the informed consent form in order to provide subjects with information 
needed to make an informed decision about whether to participate. This information 
includes the purpose of the study, the risks and benefits, and others. Moreover, one new 
element, has been added to the basic elements of informed consent, is to notify about either 
information and biospecimens collected as part of the current research might be removed 
identifiers and used for other research in the future. There are three new additional elements 
of informed consent that are a notice about commercial profits, returning of research results 
and whole genome sequencing for research involving biospecimens. 91 
 
Regarding type of consent in the Common Rule, secondary use of identifiable information 
or biospecimen allowed through study-specific consent by obtaining an IRB waiver of 
consent, or by removal of identifier. In the revision, new type of consent, “broad consent” 
is provided as alternative consent for use only for the storage, maintenance and secondary 
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use of identifiable private information or identifiable biospecimens for future unspecified 
research. In broad consent, some of the basic and additional elements from standard 
informed consent should be included. 91 
 
4.1.1.3 Example of informed consent process 
 
Accordance with regulation of informed consent, the All of Us Research Program have 
developed informed consent which has several advantages comparing to other research and 
studies. First one is electronical informed consent that is accessible through a web browser 
or application, in addition to the long-form consent. The program’s ethics review board 
have supported introducing an eConsent 92 process to ensure that potential participants have 
a clear informed consent experience regardless of their geographic location or affiliation. 
Secondly, informed consent materials of the program were written at a fifth-grade reading 
level in the United States, with animated video clips to illustrate relevant information for 
easier understanding about the research. Thirdly, a four-question formative evaluation is 
provided to participants during informed consent process for reinforcing understanding of 
the core concepts about the program and challenging misconceptions. The concept of 
formative evaluation in primary consent includes purpose of study, voluntary participation, 
ability to withdraw and risk to privacy. After evaluating participants understanding, 
signature should be obtained in the informed consent. 18 , 92 
 
To develop the most suitable consent form for the program, special team were set up. 
Before the program could began to recruit and enroll participants, the All of Us Institutional 
Review Board (IRB) had to approve All of Us protocols, informed consent and materials. 
For all studies, the IRB follows the Office for Human Research Protections’ regulations 
and guidelines, ensuring that the rights and health of research subjects are consistently 
monitored and secured. 93 
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4.1.2 South Korea 
 
4.1.2.1 Regulatory Framework 
 
Following the Belmont Report and Declaration of Helsinki, guidelines and legislation for 
clinical trials, especially in pharmaceutical field, have been developed and implemented in 
South Korea since 1995. 94 For protection of human subject in all research, the Bioethics 
and Safety Act was officially enforced in 2013 with wide coverage of not only research 
involving human subjects but also human subject materials and banking. Before this, this 
act was enacted only for regulation of embryo research, and gene banks and therapy in 
2005. 95 The Bioethics and Safety Act defines the standards for informed consent and other 
ethics and safety assurance steps as well as a framework for registering institutes that 
perform medical technology on humans, and the National and Institutional Bioethics 
Committees in South Korea.  
 
4.1.2.2 Requirements of informed consent 
 
According to Article 16 in the Bioethics and Safety Act, 96 written consent, including 
electronic version, should be obtained from human subjects of research before the research. 
This includes objectives of the research on human subject research, duration, procedure for 
and methods of participation, foreseen risks and benefits, protection personal information, 
provisions of personal information, withdrawal of consent and others. In case of subject 
who cannot give consent, informed consent should be obtained from legal representative. 
As such, every information that are included in the fully informed consent should be 
explained to everyone before obtaining the consent. Moreover, regarding research on 
human materials and human material bank, written consent should also be obtained from 
the donor of human materials. 96 In this kind of consent, key requirement is to include 




4.1.2.3 Example of informed consent process  
 
During K-MASTER project, participants who want to participate the clinical study, must 
agree and provide fully-informed consent. In this consent, purpose of research, course of 
study, possible profit and risks, the rights of participants, voluntary choice of participation, 
withdrawal information, and additional relevant information are included and participants 
are given enough time for discussion with family. When participants finalize to participate 
in the study, signature will be taken on the informed consent. 97 In order to participate in 
the National Project of Bio Big Data, participant who have indicated their intention to 
participate in the project voluntarily, will provide a consent to participate and a donation 
agreement for human materials. Since personal sensitive clinical and genetic information 
must be provided, detailed explanation of the project is given with informed consent. 35 
Along with paper based informed consent form, short video and brochures about 
explanation of consent form and its importance are provided in the website as well as in 
social networking services, like Facebook and Instagram that are commonly used by people, 





4.1.3.1 Regulatory Framework 
 
Introduction of research ethical review concept has started in 1990s in China with 
establishment of committees at big university hospitals. To protect the rights and interests 
of human subject of clinical trials, the State Food and Drug Administration and National 
Health and Family Planning Commission issued Good Clinical Practice in 1999 98 which 
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recognizes the Declaration of Helsinki as the basis for research involving humans. 
Moreover, for strengthening the protection of human research participants and the 
regulation of biomedical activities, the Ministry of Health released Interim Measures for 
the Ethical Review of Biomedical research Involving Humans in 2007 and the National 
Health and Family Planning Commission officially releases Measures for the Ethical 
Review of Biomedical Research involving Humans in 2016 which require the obtaining of 
the subject’s informed consent. 99, 100 Besides, this explained the roles and responsibilities 
of medical ethics committees, substantiated the content regarding the principles, guidelines 
and tracking of ethical review, and established the basic scope of informed consent. 
National regulations on management of human genetic resources was adopted by the State 
Council and came into force on July 1, 2019 in China.  According to the Regulation on 
Management of Human Genetic Resources in the People’s Republic of China, participant’s 
genetic data cannot be collected or used without informed consent in order to respect their 
privacy. 101 However, since the main focus of the Regulation is to secure and use human 
genetic data in China, it does not provide specific standards and requirement for informed 
consent. 101, 102 
 
4.1.3.2 Requirements of informed consent 
 
As stated in the Measures for the Ethical Review, the current main regulation on biomedical 
research, the Project investigator should obtain an informed consent form voluntarily 
signed by the subject and in case of subject or participant cannot give consent in writing, 
oral informed consent should be obtained. The contents that should be included in the 
informed consent are (1) research purpose, basic research content, process, methods and 
time limit; (2) basic information of the researcher and qualifications of the research 
institution; (3) benefits and risks associated with the research; (4) protective measures for 
the subjects; (5) security and confidentiality of research data; (6) subjects’ rights (regarding 
voluntary, withdrawal, compensation, treatment and new version of informed consent) and 
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(7) precautions for the subject. During the process of informed consent, the contents of the 
informed consent form should be explained to subject item by item according to the 
contents with subject’s understandable language and participants should be given sufficient 
time to understand and make decision. 100 When there are changes in research scope, 
program and content or to use identifiable information and biological samples in new 
research, informed consent have to be obtained from subjects again.  
 
 
4.1.3.3 Example of informed consent process  
 
The Cohort study involving northwest and southwest region have obtained written 
informed consent from all participants or legal representatives before collecting 
information and biospecimens for the study. Written informed consent was approved by 
the Ethics Committee for research involving human subjects in Xi’an Jiao tong University 
Health Science Center and Sichuan University.  
 
 
4.1.4 Mongolia  
 
4.1.4.1 Regulatory framework 
 
Following footsteps of other countries, international ethical principles and guidelines for 
research, especially in human subject research, such as Nuremberg Code, Belmont Report 
and so on, have been reflected in Mongolia to develop and implement universal ethical 
principles and regulatory frameworks. In 2002, Medical Ethics Review Committee was 
established under Ministry of Health to regulate projects, clinical trials in treatment and 
other researchers in Mongolia. Besides, international ethical guidelines for biomedical 
research including “Operational guidelines for ethics committee that review biomedical 
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research” (WHO, Geneva, 2000), “Ethical Guidelines for Biomedical Research Involving 
Human Subjects” (CIOMS 2002) and “Declaration of Helsinki” have been translated and 
implemented in biomedical research fields with detailed informed consent process. 
Afterward, in 2007, Ministry of Health established official order named “Guideline and 
principles for Medical Ethical Review Committee” to manage process related to researches.   
 
In 2018, new codes and principles regarding Medical Ethical Review Committee (Order 
No. A/217) was renewed by Minister of Health, Mongolia to coordinate the activities of 
the Ethical Review Committee that are to protect human rights, to conduct research 
involving human subjects with ethical standards, especially in biomedicine, epidemiology, 
observational and experimental research. 103 Under this order, Ethical Review Committee 
should follow all related legal acts and ethical guidelines, such as Declaration of Helsinki 
(2014) and Ethical Guidelines for Biomedical Research Involving Human Subjects 
(CIOMS 2002) to evaluate informed consent and approve it. Besides, there is a separate 
Regulatory Order for collecting and using human blood, blood products, biological fluids, 
tissues and organs for the purpose of clinical trials and research that was established in 
2018 by the Order of the Health Minister, No. A/526. To collect biospecimens for clinical 
trials and research, informed consent has to be taken from participant and Ethical Review 
Committee must give approval for the research including the informed consent process and 
contents. 104 
 
4.1.4.2 Requirements of informed consent  
 
As stated by this order and Ethical guidelines for Biomedical Research Involving Human 
Subjects, written informed consent (can be orally) must be obtained voluntarily from 
subjects or legally authorized representative in case of individual who is not capable of 
giving informed consent. 103 Moreover, the investigator must explain the information in 
accordance with level of subject’s understanding, answer all questions honestly to help 
 39 
decision making of participation, and give enough time to discuss with family before 
signing the consent form. The information that should be provided in the informed consent 
are (1) purpose of research, procedures, research design, and duration, (2) research findings 
and accessibility to data, (3) foreseeable risks, pain or discomfort, and benefits, (4) privacy 
and confidentiality, especially in genetic information, (5) direct or secondary use of 
medical records and biological samples for research, (6) compensation, and (7) affiliation 
of researchers and sponsors.  Depending on types of research and target groups, special 
principles and information in the informed consent are applied for the means of protecting 
subjects’ rights and eligibility.  
 
Table 3. Differences of regulation, contents and type for informed consent 






















Future use of 
records and 
biospecimens 








Electronic Oral Oral 
 *Department of Health & Human Services and U.S. FDA http://fda.gov/ ; 
National Institutes of Health – All of Us Research Program. 
https://allofus.nih.gov/ 
**Korean Legislation Research Institute – BSA http://elaw.klri.re.kr/  
 ***National Health Commission of the People’s Republic of China - Measures of 
the Ethical Review of Biomedical Research involving Humans;  
**** New codes and principles regarding Medical Ethical Review Committee (Order No. 
A/217), 2018 www.legalinfo.mn 
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4.1.5 Proposed recommendation to Mongolia 
 
In context of informed consent, there are several similarity and difference in the regulation 
and requirements of US, South Korea, China and Mongolia. Firstly, some contents 
(elements) of information that are required to be included in informed consent are ideal in 
all countries, but other elements are varying by stating in one or 2 countries. Besides, 
considering development of precision medicine and genomic analysis, informed consent 
requirements and elements are updated in USA’s Common Rule. But, it is difficult to 
criticize one from another, even Nuremburg Code, Belmont Report and Universal 
Declaration of Helsinki are being upgrading and revising based on situation of legislation 
and principles. Secondly, regarding subject’s comprehension and understanding, South 
Korea and China’s regulation stated that every information in the informed consent should 
be explained one by one, while US’s recent revision applied new requirement to include 
key information in the beginning of the consent. But in Mongolia, it is stated that researcher 
should explain informed consent at the same level of participant’s understanding and 
answer participant’s all questions regarding the consent form. Thirdly, voluntary of 
informed consent is applied to all three countries according to the regulations. However, 
still, informed consent rises debate among researchers due to large-scale research project 
that collect, store, re-use and manage data, especially genetic information.  
 
Table 4. Three pillars of informed consent in US, South Korea, China and Mongolia  
 Disclosure of 
Information 
Subject’s comprehension  Voluntary 
United States 
(Common rule) 
- Basic elements (9), 
- Additional elements 
(9) 









- contents (7) - explanation 
- sufficient time 
 
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 Disclosure of 
Information 




- contents (7) - explanation 
- sufficient time 
 
 
Through the analysis, it has clearly revealed that Mongolia need to improve regulation 
related to informed consent as followed. First, appropriate language and terms that 
participant can understand without problem should be used and explained in the informed 
consent. Since precision medicine is new term in Mongolia, general population as well as 
some of help professionals do not have any knowledge or information about it. As US and 
South Korea’s project team developed animated videos with informed consent to make 
participant understand fully about the research. This kind of educational interventions or 
approach will help comprehension of research related information in informed consent and 
result in right decision for the participation. In addition, promoting all information about 
research through social network and television is another approach to improve public 
awareness and understanding.  
 
Second, it is necessary to develop formal questions or quizzes to assess level of 
understanding of participants, especially in context of key information, including purpose 
of study, study methods, duration, rights and risk and benefits. The ethical guideline in 
Mongolia did not cover evaluation of understanding, only stated about asking questions 
from researchers regarding informed consent information. Moreover, several studies on 
informed consent showed that participants are not aware of rights to withdrawal or refusal 
to participation, even it is included in the consent form. So that, it is fundamental to educate 
or inform well about rights to withdrawal to public, including participants or patients.  
 
Third, electronic informed consent needs to be carefully considered in Mongolia to open 
possibility for enrolling various ethnic population. It has started to be approved and used 
in many studies, like precision medicine cohort study involving various diversity of people 
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from many places, regardless location. Also, enhanced IT and digital technologies allows 
more opportunities to evolve informed consent to electronic version with numerous 
advantages. But in Mongolia, special contemplation should be discussed in order to 
develop electronic informed consent due to nomadic life, lack of infrastructure, like internet, 
computer in remote areas, and low computer and health literacy, especially in non-capital 
areas. For this reason, there are many preparations that need to be done by government as 
a national strategy, such as improving literacy amongst population, and infrastructure in 
remote areas. As another option, informed consent could be obtained from non-capital 
areas or nomadic population with traditional approach – like explaining informed consent 





4.2.1 United States 
 
4.2.1.1. Regulatory framework 
 
To date, health-data and new legislation proposals in United States have appeared to 
emphasize privacy by restricting or regulating access health-relevant data rather than 
ensuring its availability for uses that might enhance person and population health. The 
Health Insurance Portability and Accountability Act of 1996 (HIPAA) and the Health 
Information Technology for Economic and Clinical Health Act (HITECH) of 2009 have 
extensive privacy, security and violation notification regulations but only for data inside 
the health care system.  
 
The HIPAA Privacy Rule establishes adequate protections to protect the privacy of 
personal health information, as well as restrictions and limitations on the uses and 
disclosures of such information that are permitted without patient authorization. 105 All 
“individually identifiable health information” is protected by the Privacy Rule and it is 
called as Protected Health Information which includes one or more of the 18 identifiers 
( e.g., name, address, birth date, social security number) as stated in HIPAA. Regarding 
genetic information, there are no special protection in the Privacy Rule and it is placed 
under the ordinary protections. In case of removal of these identifiers, it is De-Identified 
Health Information that results no restriction on use or disclosure meaning not protected 






4.2.1.2 Privacy protection method – De-identification 
 
The standard and implementation specification for de-identification of protected health 
information is provided in the HIPAA Privacy Rule, Section 164.514. According to this 
rule, there are 2 de-identification methods, including Expert Determination and Safe 
Harbor. The Expert Determination method provides an expert to review personal 
information and establishes an appropriate de-identification method by applying statistical 
or scientific principles that minimizes the risk of re-identification. For example, k-
anonymity technique which replace certain values of the attributes by an asterisk or with 
broader category, can be used in this method to de-identify. 82 The Safe Harbor method 
applies to remove 18 specific identifiers of the data. 107 Although, neither method is a safe 
de-identification method with no risk of re-identification, they enable processing and 
sharing of de-identified data while lowering the risk of re-identification. But, genetic 
information is not considered as one of 18 specific identifiers, even though it can be used 
to identify individual because genetic information, itself determine each person and differ 
from each other. 108  
 
4.2.1.3 Example of privacy protection  
 
PMI-AURP have developed Data Security Policy Principles and Framework to guide 
decision-making in precision medicine activities. Data Security Principles intended to 
assist organizations in establishing and implementing a proper security plan in uses of the 
data. One of the frameworks to organize data security programs in PMI-AURP, is 
developed by the National Institute for Standards and Technology (NIST) which consists 
of five functions to assess cybersecurity and data security performance. 93 In addition, data 
that are accessible to researchers are de-identified by removing names and other identifying 
information with following all federal laws and regulations.  
  
 45 
4.2.2 South Korea 
 
4.2.2.1 Regulatory framework 
 
Like many other countries, South Korea have implemented precision medicine, and 
developed legal and administrative frameworks for privacy of personal and health-related 
information. In 2011, Personal information Protection Act (PIPA) enacted with purpose to 
protect the freedom and rights of individuals, and further, to realize the dignity and value 
of the individuals by prescribing the processing and protection of personal information. 
According to PIPA, personal information defined as information applicable to any living 
person that makes it possible to identify such individual by name, registration number, 
address etc. but, DNA information and biometric information are clearly stated as 
“sensitive information” which is defined in Article 18 of Enforcement Decree of the PIPA 
with criminal record, and racial or ethnic origin information. 109  
 
Separately, the Bioethics and Safety Act is frequently applicable when it comes to the use 
of health and medical data. Biospecimen research, in particular, is only permitted under 
this Act if a research proposal has been approved by an IRB and biospecimen donors have 
given their written consent. On the other hand, the Bioethics and Safety Act describes 
genetic information as “information about an individual’s genetic characteristics obtained 
through the analysis human body components or biospecimens” (Article 2). While this 
definition helps to distinguish genomics research and resolve concerns about 
discrimination, it also addresses privacy aspects. 110 All that personal information should 
not be provided to third party unless consent is taken from the participant or special 




4.2.2.2 Privacy protection method 
 
In 2020, amendment to the Personal Information Protection Act was passed by the National 
Assembly by introduction of the concept of pseudonymized information for statistical and 
research purposes. 111 According to the amendment, pseudonymization refers to process of 
removing or replacing identifiers of personal information that requires additional 
information for identification and personal information controller can process 
pseudonymized information without the consent of the data subject only for purposes of 
statistic, scientific research and public data preservation. However, anonymous information 
that cannot be identified even if it is combined with additional information is not part of 
personal information 109 and can be use more freely.  
 
The Guidelines for De-Identification of Personal Data was published under joint leadership 
of the Korean government including ministries and commission in 2016 in order to safely 
utilize the information with standards of de-identification, measures and scope of use. In 
accordance with the guidelines, there are 5 methods and 17 detailed techniques for de-
identification. 5 methods are pseudonymization, aggregation, data reduction, data 
suppression and data masking. For pseudonymization method, heuristic pseudonymization, 
encryption and swapping techniques can be used as explained in the guidelines. 112 
However, privacy protection methods that are included in this guideline are not suitable 







4.2.2.3 Example of privacy protection 
 
The National Project of Bio Big Data complies five principles, including principle of 
minimum collection, principle of prohibition of use for other purposes, principle of data 
quality assurance, principle of transparency, and principle of data safety management in 
order to protect the personal information of participants. The information provided by the 
participant and human biospecimens such as blood and saliva are safely stored at the 
National Central Human Resources Bank of Korea Disease Control and Prevention Agency 
(KDCA). Individual clinical information and genetic information collected for research are 
provided to researchers through de-identification processing at KDCA so that it is never 
known who provided the information. Researchers who want to use the provided data can 
use the information only when they submit a research proposal and pass the deliberation of 
the Research Ethics Committee. All research processes conducted by researchers are 
conducted only within a closed research platform that can be monitored by the state and 




4.2.3.1 Regulatory framework 
 
In terms of privacy and personal data protection, China lacks special legislation at the 
national level to protect personal data- including genetic data – and privacy. However, in 
context of Direct-to-consumer (DTC) genetic testing services, related laws and standards 
apply to protect customers’ personal information including genetic data. The SCNPCC 
promulgated the Cybersecurity Law of the People’s Republic of China in 2017, which 
states that DTC genetic testing providers must not steal or use other illegal means to obtain 
consumers’ personal information, including biometric information, nor sell or provide 
consumers’ personal information to others. 114 In addition, China’s National Information 
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Security Standardization Technology Committee published the Personal Information 
Security Specification in 2017, revision in 2020, a national standard that governs the 
collection, storage, use, transfer and disclosure of personal data. Personal genetic 
information is classified as personal sensitive information and is specifically identified as 
a type of biometric information. 115  
 
In October 21, 2020, a draft of China’s Personal Information Protection Law was published 
for a month-long public comment period. Once it is implemented, the Personal Information 
Protection Law (PIPL) will be a central and universal governing law for protecting personal 
information in China. According to Article 4 of the Draft, personal information applies to 
“all kinds of information” about identified or identifiable natural persons that is registered 
electronically or otherwise, but does not include information that has been anonymized. 
Sensitive personal information is defined as personal information about ethics, race, 
religious beliefs, personal biometrics, medical health, financial accounts and personal 
whereabouts that, if leaked or improperly used, may lead to discrimination or seriously 
endanger personal or property protection. 116 Under the Draft PIPL, individual consent 
should be obtained voluntarily for personal information processing, such as collection, 
storage, use, processing, transmission, provision and disclosure of personal information. 
Anonymized information is no longer considered as personal information (Article 4). 116 
 
4.2.3.2 Privacy protection method 
 
In the revision of the Personal Information Security Specification, 117 the principles and 
security requirements are stated as term of anonymization and de-identification with 
definition, technical methods and application in the process of regulating personal 
information. For technical methods, k-anonymity from anonymization, and 
pseudonymization, encryption and hash functions from de-identification were mentioned. 
In addition, the National Information Security Standardization Technical Committee of 
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China implemented a national standard entitled Information Security Technology – 
Guidelines for De-Identifying Personal Information to describe the goals and principles of 
de-identification of personal information, and proposed the process of de-identification and 
management measures. Common de-identification techniques (statistical tools, 
cryptographic tools, suppression, pseudonymization, generalization and randomization) 
and models (k-anonymity and differential privacy), and their characteristics and selection 




4.2.4.1 Regulatory framework 
 
The State Great Hural (the Parliament) of Mongolia adopted the Law on Personal Privacy 
in 1995 in accordance with the Constitution of Mongolia, which applies for the protection 
of personal secrets. The Law on Personal Secrecy (Privacy Law) specified the right in detail, 
classifying it into five categories, such as health information secrecy. The government 
should protect citizens’ secrets in compliance with procedures and on legal grounds, 
according to the Privacy Law. Only officials of designated state agencies have access to 
citizens’ personal data, which is kept according to procedures and on ground determined 
by law. Furthermore, the law forbids the disclosure of a person’s private information 
obtained by legal processes and on legal grounds. An individual who violates the law and 
exposes a person’s private data in an unauthorized manner will be punished by the court. 
119 However, this law wasn’t sufficient for regulating results of rapidly evolving technology. 
 
In 2021, the Ministry of Justice and Internal Affairs proposed Draft of “Personal 
Information Protection Law” 120 to the Parliament for approval. The draft of law has total 
of 8 chapters and 29 articles and is aimed to regulate collection, processing, use and privacy 
of personal information. Along with personal information, biometric and genetic 
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information are specifically defined and considered as “personal sensitive information”. 
All information, in particular sensitive information should be collected, processed and used 
with written consent (or electronically) of the owner. It is allowed to process or use 
information in case of removal of personal identifier. But, de-identification terms, methods 
and techniques are not stated in detail under the draft.  
 
Table 5. Privacy regulation, guidelines for de-identification and methods in US, South 
Korea, China and Mongolia  
 US* South Korea** China *** Mongolia**** 
Law & 
Regulation  








  Draft of PIPL 
(2021) 





















- Safe Harbor 
- 5 methods  
- 17 
techniques  




*Department of Health & Human Services – HIPAA Privacy Rule http://hhs.gov/ ;  
**Korean Legislation Research Institute – PIPA http://elaw.klri.re.kr/ ; Guidelines for 
De-identification of Personal data (http://privacy.go.kr/ ) 
 ***The Draft of Personal Information Protection Law and Personal Information 
Security Specification (2020); Information security technology - Guide for De-
Identifying Personal Information (http://chinesestandard.net/ ) 
****Integrated Legal information System - The Law on Personal Secrecy (Privacy 
Law), www.legalinfo.mn  
Draft of Personal Information Protection Law ( http://mojha.gov.mn )  
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4.2.5 Proposed recommendation to Mongolia 
 
Regarding privacy, main legal regulatory framework for health data protection had 
officially applied in US and South Korea as Privacy Rule and PIPA, respectively. However, 
there is no special legislation for privacy at the national level in China yet, instead personal 
information protection is governed by the Personal Information Security Specification as 
national standard in data collection, use, transfer, storage and disclosure, and the 
Cybersecurity Law, related to direct-to-consumer. Recently, Draft of Personal Information 
Protection Law introduced in 2020 to public for feedback but has not officially 
implemented in China. At the same time, Mongolia also developed Personal Information 
Protection Law in 2021 which is under approval process by Great Khural.  When those 
legislations are enacted in China and Mongolia, Personal Information Protection Act will 
be key regulatory law in privacy issues of personal information, including genetic 
information and biometric information. 
 
All countries, except Mongolia applied a statement about de-identification of personal 
information in the legislation accordingly. Related to this, guidelines for de-identification 
of personal information is published in South Korea and China, separately as the national 
standards. But, Privacy Rule of US includes guidance of de-identification standards and 
implementation specifications as whole regulation. Guidelines for de-identification in each 
country explained techniques and methods with detailed instructions. From de-
identification methods, pseudonymization is articled in the PIPA of South Korea and Draft 
of PIPL of China. As technology expands, de-identification methods are being newly 
developed based on characteristics of data and purpose of the researches. So that, it is 
impossible to define the most effective method just by comparing, but the most concerning 
thing is risks of re-identification in every country. 
 
Since Mongolia is taking first step in privacy protection in context of personal information 
and sensitive information including genetic and biometric, several updates and 
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recommendation could be proposed based on described approaches and solution ways from 
respective countries.  
First, although new privacy law is under progress of approval in Mongolia, it needs to be 
implemented officially to provide privacy protection since there is no official legislation or 
standard for privacy until now. In addition, de-identification definition and process need to 
be enacted in the Personal Information Protection Law. Identifiers need to be defined and 
listed in the law to avoid hesitation for personal information. For instance, US defined the 
18 identifiers that need to be removed for de-identification so, it makes easier for 
researchers and experts.  
 
Second, it needs to develop a guideline for de-identification of personal information to 
improve data protection with advanced techniques, especially in processing of a huge 
amount data which arises privacy issues. Except from Mongolia, each country has 
guideline or guidance for de-identification methods based on type of data and process of 
data. This kind of guideline helps better protection of personal information, especially 
sensitive information, even though re-identification problem is another obstacle that come 
out from experiences in these countries and also due to advanced technologies.  
 
Lastly, with above recommendations, building capacity for human resources and 
technology is essential in improvement of privacy protection. Professional experts can 
determine and define suitable methods or technique to use in privacy protection based on 
countries and research characteristics, and ability of technology. So, enhancing them will 
bring many advantageous changes in personal and health information protection, especially 
in future of biomedical research in Mongolia. Moreover, experience from developed 





Chapter 5. Discussion  
 
Current status of precision medicine in countries were determined through literature review 
and actual examples of program. In addition, along with precision medicine studies, its 
informed consent and privacy issues were identified with other countries experiences. By 
comparison, countries current regulation and legislation in context of informed consent and 
privacy were determined and made background for improvement recommendation to 
Mongolia.  
 
Informed consent, as pre-stage of Precision Medicine in Mongolia, there are many changes 
and improvement that should be delivered to researchers and policy-makers in preparation 
based on US, South Korea and China’s experiences. Many recent studies in these countries 
are showing that written informed consent is converting into electronic version with 
additional multimedia approaches. This approach includes short-length videos with 
graphics and icons to improve understanding of information in informed consent more 
comprehensively. In addition, developing evaluation questions for research participants 
before signing the consent is another approach to assess understanding level and further 
improvement in consent form. But it needs to be careful consideration and preparation in 
evaluation questions because some participants may think it as kind of tests and results 
burden to participants. Depending on health literacy, there are some difficulties in 
terminology to understand that requires understandable translation and education using 
medias to general population. Even tough, electronic informed consent shows good impact 
comparing to paper-based consent form, printed consent should be provided to participants 
as well. For this reason, US, Korea and China allows both written and electronic informed 
consent in their legislation. Because of Mongolian nomadic life, less development of 
infrastructure and low computer literacy, it may result obstacles in obtaining electronic 
informed consent, especially in remote areas. For this reason, process of informed consent 
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in Mongolia need to be various depending on living condition to enroll large diversity of 
participants for development of Precision Medicine.   
 
Privacy issues are still complicated in many countries due to advanced technologies in very 
short time. But, as shown in US, South Korea and China, law on personal information 
protection is very required, especially in era of precision medicine from prospective of 
ELSI researchers. Personal information protection law will provide detailed regulation 
regarding privacy issues that arose in many countries as reflection of future medicine. 
Along with this act, de-identification term and methods need to be developed in Mongolia 
to assure privacy into next level. Until now, several types of methods and techniques are 
developed around the world but every country select or develop suitable methods based on 
the countries needs and requirements. Therefore, professionals should develop guidance to 
manage large-amount of data. Along with it, human resource training and infrastructure 
preparation in Mongolia are required as well as awareness of privacy importance to public 
with education. It will result in more familiarities in privacy concerns of public side.  
 
This study contained several limitations as followed. Firstly, precision medicine 
development as well as its infrastructure in US, South Korea and China is not comparable 
to current Mongolian situation. There are many barriers in Mongolia. Secondly, the reports 
or guidelines have been studied may have possibility of updating issue which is a risk that 
may not be included in this research. The study was conducted only the literature review 
from academic journals, national and international guidelines and legislation. So, it lacks 
experts’ viewpoints from law and guidelines. In addition, examples of precision medicine 
research in the countries are not completed and well-introduced due to scarcity of official 
information through literature review. Especially in China, there are several cohort studies 
that are conducted and now in follow-up stage but detailed information regarding informed 
consent and privacy are not provided.   
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Chapter 6. Conclusion 
 
Precision medicine has been showing many good results and improvements in the countries, 
especially in the diagnosis and treatment of cancer and rare diseases. Along with innovation, 
there are challenges that follows and rises due to new discovery and advancement. So that, 
countries keep upgrading their policy and regulation according to level of expansion of 
medicine which can protect and prevent population from any kinds of risks and harms. In 
particular, informed consent and privacy issues are the most common issues that get many 
attention and concerns from population and researcher as well as policy-makers in the field 
of modern research. Finding ways to ease problems and issues with legal and regulatory 
frameworks is possible way to avoid the complications and disillusionment experienced 
with precision medicine- ELSI issues from countries.  
 
This study’s recommendations will help on policy development of the precision medicine 
and further improvement regarding ELSI issues in Mongolia. I found that legal and 
regulatory frameworks of informed consent and privacy in Mongolia has been slowly 
following international steps to prepare for future development of precision medicine. 
However, there are still many barriers that need to be removed to build strong ethical, legal 
and social protection to human subjects especially in cases of informed consent and privacy 
in Mongolia comparing to US, South Korea and China. Furthermore, detailed analysis from 
expert’s perspective will need to be conducted in the future for achieving successful 
improvement from international experts’ experiences and support. To conclude, this study 
expect to Mongolia may need to be well prepared in implementation of precision medicine, 
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